A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-11-25
AEs
4
Serious
1
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 3); relationship: not assessed
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 28); relationship: N
severe
serious
assessed
Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 48); relationship: not assessed; serious criteria: life-threatening
mild
assessed
Grade 1 Decreased appetite — outcome: UNKNOWN; onset 2023-02-22 (study day 84); relationship: not assessed
Data queries
No data queries.